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Introduction
Left ventricular hypertrophy (LVH) is a frequent and
well-recognized consequence of a chronically elevated
blood pressure (BP). Several studies have demon-
strated that LVH is an independent cardiovascular risk
factor, associated with an increased likelihood to
develop cardiovascular complications such as conges-
tive heart failure, sudden cardiac death, coronary
heart disease and stroke [1,2]. Conversely, an aggres-
sive treatment of hypertension can prevent and reverse
LVH and reduce the incidence of cardiovascular
events [3,4].
Non-haemodynamic factors leading to LVH
If BP is definitively the major trigger for the develop-
ment of cardiac hypertrophy in hypertension, left
ventricular mass may be affected by several other
non-haemodynamic factors which may also play an
important role in the pathophysiology of LVH, as
listed in Table 1. Factors such as gender, age, race,
obesity, alcohol consumption, catecholamines, ANP,
aldosterone and angiotensin II and genetic factors
(polymorphism of ACE) have all been considered as
BP-independent determinants of left ventricular struc-
ture. However, in clinical conditions, it is often difficult
to demonstrate that the effect of these factors is really
independent of BP, because small but long-standing
changes in BP, which may contribute to the develop-
ment of LVH may be missed, such as for example,
nighttime increases in BP. Indeed, the discrimination
between normotension and hypertension is arbitrary
and a loss of the normal nocturnal decline in BP has
been associated with an increased incidence of LVH
[5]. Similarly, an excessive rise in BP may induce LVH
in subjects who participate in vigorous but unsustained
exercises.
Experimental studies in transgenic mice have some-
times provided good evidence that some of these
factors induce cardiac hypertrophy, independently of
changes in systemic BP. For example, the over-
expression of angiotensinogen in cardiomyocytes
leads to an increased production of angiotensin II
limited to the heart with normal plasma levels [6].
Interestingly, these transgenic mice develop a marked
cardiac hypertrophy in the absence of systemic
hypertension and the increase in cardiac mass could
be prevented by the administration of a blocker of the
angiotensin II AT1 receptor [6]. In another transgenic
mice model, inactivation of the guanylyl-cyclase-A
gene selectively in the heart has been found to exhibit a
mild cardiac hypertrophy, a marked increase in mRNA
expression of cardiac hypertrophy markers, but a 7–
10mmHg lower BP than control mice [7]. In some
experiments, a regression of LVH was found without
a decrease in BP [8,9]. For example, non-selective
blockade of endothelin receptors with bosentan has
been found to lower cardiac hypertrophy without
lowering BP [8]. A similar observation was made with
the inhibition of the transcription nuclear factor (NF)-
kB in spontaneously hypertensive rats [9]. Taken
together, these experimental data suggest that there
are definite mechanisms which contribute to the
development of cardiac hypertrophy independently of
BP, but their role in humans remains to be
demonstrated.
Does sodium have a role in the development of LVH?
There is also increasing evidence that a high salt intake
may have deleterious effects on the cardiovascular
system and lead to the development of cardiac and
vascular hypertrophy, independently or in addition
to its effect on BP [10–12]. However, once again,
it is difficult to ascertain whether the impact of the
high sodium intake on cardiac mass or vascular
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hypertrophy really is independent of BP, unless this
latter is measured carefully over 24 h, which was not
the case in these studies. Indeed, BP during sleeping
hours may be crucial for the development of LVH even
in animals [13].
In rats, increasing the sodium content of the diet
often increases BP but there are some reports suggest-
ing that sodium may induce LVH even in normo-
tensive animals [14]. We recently investigated the
combined effects of sodium and mineralocorticoids
on BP and cardiac and renal hypertrophy in two
strains of mice, one carrying one renin gene (the Ren-1c
gene) and a second one carrying two renin genes, i.e.
the Ren-1d and the Ren-2 genes [15]. The major
difference between these two strains is that the two-
renin gene mice exhibit a 10-fold higher plasma
renin activity and a 100-fold higher plasma renin
concentration, which are not suppressed by a high
sodium intake. Two-renin gene mice are salt sensitive
and have a higher baseline BP. When these mice are
uninephrectomized and receive a 1% sodium diet
together with deoxycorticosterone for several weeks,
their BP increases markedly and they develop a
significant cardiac hypertrophy and an increase in the
mass of the remaining kidney. To our surprise, mice
with only one renin gene exhibited no increase in BP
when receiving DOCA/salt. However, these animals
also develop cardiac and renal hypertrophy. These
data therefore suggested that sodium, when added to a
high dose of mineralocorticoids, could contribute to
induce cardiac and renal hypertrophy, even in the
absence of BP changes [15]. To further investigate
the respective role of mineralocorticoids and sodium in
the development of cardiac hypertrophy, the same one-
renin gene mice were treated for 4 weeks with DOCA
and either a low or a high sodium diet [16].
Interestingly, mice receiving DOCA and a low
sodium diet develop all the signs of hypermineralo-
corticism but no significant increase in cardiac mass
(Figure 1). These data indicate that an excess of miner-
alocorticoid per se is not sufficient to induce cardiac
and renal hypertrophy and the presence of a high
sodium intake is a necessary condition for the
development of mineralocorticoid-induced cardiac
and renal damages.
To further explore the role of mineralocorticoids and
sodium in the development of cardiac hypertrophy, we
examined the direct consequences of chronically
elevated plasma aldosterone levels on cardiac mass in
a mouse model (a epithelium Na channel -/- Tg), which
is normotensive under a normal sodium diet but
exhibits chronic hyperaldosteronism [17]. After birth,
these mice develop a pseudohypoaldosteronism type 1
(PHA-1) characterized by a metabolic acidosis, urinary
salt wasting and growth retardation. Within 2 weeks
after birth 50% of these mice die, but the survivors
develop a compensated state of PHA-1 with a normal
acid-base status, a compensated salt wasting and 6-fold
higher plasma aldosterone levels than control. These
mice and their control were examined after 16 months
of life. We found that despite chronically elevated
aldosterone levels and a low BP, these mice had no
evidence of cardiac hypertrophy, remodelling or
fibrosis [17]. Therefore, this observation suggests that
hypermineralocorticism does not induce cardiac hyper-
trophy in mice with a urinary salt wasting phenotype.
This further emphasizes the importance of sodium as
an important cofactor for the development of cardiac
hypertrophy and that a hypermineralocorticism per se
has little if any effect on the heart, unless animals
receive a high sodium intake.
In more recent studies, we have shown that
metabolic factors other than sodium may contribute
to the development of cardiac hypertrophy in the
DOCA/salt mice model. Indeed, the DOCA/salt
model is characterized by the development of hypoka-
laemia and metabolic alkalosis. We demonstrated
that these two factors may also participate in the
Table 1. Non-haemodynamic factors and the development of left
ventricular hypertrophy
Factor Level of evidence
Gender þþ
Race þþ
Age þþ
Genetic þ
Obesity þþþ
Alcohol þþ
Insulin resistance þþ
Sodium intake þþ
Hypokalaemia þ
Angiotensin II þþ
ANP þ
Catecholamines þ
Aldosterone þ
Parathyroid hormone þ
NF-kB þ
þþþ: Very strong evidence, þþ strong evidence, þ evidence that
needs confirmation. The evidence is based on clinical and experi-
mental data.
Control High salt
(HS)
Low salt
(LS)
DOCA/LSDOCA/HS
0
1
2
3
4
5
6
P<0.01 P<0.01
Cardiac weight index(mg/g)
Fig. 1. Effect of a high and low sodium diet on cardiac weight index
in deoxycorticosterone-treated mice. BP was normal and comparable
in all groups. Cardiac hypertrophy was found in one-renin gene mice
receiving DOCA and a high salt intake (1% NaCl in the drinking
water). No cardiac hypertrophy was observed on a low sodium diet
(0.5mg Na/g food). Adapted from references 14 and 15.
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pathophysiology of cardiac hypertrophy, as correction
of the hypokalaemia can prevent the development of
cardiac hypertrophy without affecting BP [18]. These
data suggest that there might be an interaction between
the high-salt intake and the mineralocorticoid-induced
loss of potassium to trigger hypertrophic factors
leading to cardiac hypertrophy. Yet, other factors
may contribute to the development of LVH in the
mineralocorticoid-salt-induced model, including the
alkalosis itself and the development of hypomagnesae-
mia, which has also been reported to accompany
mineralocorticoid excess and to interact negatively
on heart function with the development of hypo-
kalaemia [19].
What is the normal BP in mice with cardiac
hypertrophy?
The development of cardiac hypertrophy in the
presence of a so-called ‘normal’ BP might raise the
question of the normality of BP. One could postulate
that there is a resetting of the BP/cardiac hypertrophic-
response relationship and that in this situation a lower
BP could perhaps prevent the occurrence of cardiac
hypertrophy. To test this hypothesis, we recently
treated normotensive DOCA/salt mice with a calcium
channel blocker, in order to lower their ‘normal’ BP
and to assess the impact of lower BP on cardiac
hypertrophy. To our surprise, reducing BP in these
mice was associated with a reduction in cardiac mass,
as shown in Figure 2 [20]. These results would thus
suggest that there is indeed a resetting and that in
the presence of LVH, one should perhaps aim at a
lower BP.
Conclusions
LVH is an independent risk factor for the develop-
ment of cardiovascular complications in hypertensive
patients. Although BP is the major trigger for the
development of LVH, several non-haemodynamic
factors should also be taken into account, including
sodium and potassium intake. Recent animal
data have indeed suggested that a high sodium intake
is a crucial cofactor contributing to the patho-
physiology of cardiac hypertrophy, particularly in
situations of mineralocorticoid excess. These observa-
tions further emphasize the importance of non-
pharmacological recommendations in the management
of hypertensive patients, in order to prevent target
organ damages.
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Introduction
Iron deficiency is a frequent complication in patients
with chronic kidney disease (CKD). Major causes are
reduced dietary intake, impaired absorption, chronic
blood loss, inflammatory or infectious comorbidity
and increased requirements during correction of renal
anaemia with erythropoiesis-stimulating agents (ESA).
Inadaequate iron stores with reduced availability of
iron to the bone marrow are the main cause of
hyporesponsiveness to ESA treatment. Thus, in the
vast majority of haemodialysis patients, intravenous
iron is used in combination with ESA to treat renal
anaemia. Optimal iron management, therefore,
includes the monitoring of iron status and the
supplementation of adaequate amounts of iron, to
maintain haemoglobin levels at target in a cost-
effective manner [1].
Monitoring iron status
Ferritin
Serum ferritin is a parameter of iron storage in the
reticuloendothelial system. In subjects without kidney
disease, a value below 15 ng/ml indicates absolute iron
deficiency [2]. In CKD patients, absolute iron
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